...
首页> 外文期刊>Expert Opinion on Therapeutic Patents >Muscarinic acetylcholine receptors as effector sites for present and future therapeutic applications: focus on non-neural cholinergic systems
【24h】

Muscarinic acetylcholine receptors as effector sites for present and future therapeutic applications: focus on non-neural cholinergic systems

机译:毒蕈碱乙酰胆碱受体作为当前和未来治疗应用的效应子部位:专注于非神经胆碱能系统

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This review summarises the expression and function of muscarinic acetylcholine receptors (mAChR) in the organism, and the therapeutic implications of recent patents on cholinergic agents. Aside from the well known therapeutic applications of parasympathomimetic and -lytic drugs for diseases of the heart, eye, circulation and airways, new possible fields for mAChR agonists and antagonists in clinical therapy have begun to emerge. In particular, the role of non-neural cholinergic mechanisms in tissue regeneration, development and even carcinogenesis has become increasingly studied by a number of research teams within the last decade. This review exemplifies and contrasts experimental findings of mAChR drug action, and discusses these with regard to patents from the past 4 years.
机译:这篇综述总结了毒蕈碱乙酰胆碱受体(mAChR)在生物体中的表达和功能,以及有关胆碱能药物的最新专利的治疗意义。除了用于神经,眼,循环和气道疾病的拟副交感神经药和裂解药物的众所周知的治疗应用外,mAChR激动剂和拮抗剂在临床治疗中的新可能领域也已开始出现。特别地,在过去十年中,许多研究团队越来越多地研究了非神经胆碱能机制在组织再生,发育乃至癌变中的作用。这篇综述例证并对比了mAChR药物作用的实验发现,并就过去4年的专利对这些发现进行了讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号